Skip to main content
. Author manuscript; available in PMC: 2023 Apr 6.
Published in final edited form as: Hepatoma Res. 2023 Mar 17;9:7. doi: 10.20517/2394-5079.2022.85

Table 4.

Clinical laboratory analytes of Pacific Island patients with HCC

PI-born (n = 92) US-born (n = 153) P value Unadjusted OR, 95%CI
Albumin (mg/dL) 3.24 ( 0.77) 3.54 ( 0.65) P = 0.003
Bilirubin (mg/dL) 2.42 ( 4.30) 2.14 ( 4.11) P = 0.62
Creatinine (mg/dL) 1.26 ( 0.97) 1.09 ( 0.71) P = 0.14
Platelets (x103/μl) 178 ( 101) 179 ( 90) P = 0.98
INR 1.24 ( 0.28) 1.18 ( 0.22) P = 0.06
Median AFP (ng/dL 25.9 34.8 P = 0.90
Normal AFP (< 20 ng/dL) 41 (45%) 56 (38%) 1.33 (0.79–2.26)
Mean MELD score 12 ( 5) 11 ( 5) P = 0.09

HCC: Hepatocellular carcinoma; PI-born: Pacific Island-born; NASH: nonalcoholic steatohepatitis; NAFLD: nonalcoholic fatty liver disease; BCLC: barcelona clinic liver cancer; INR: international normalized ratio; AFP: alpha-fetoprotein; MELD: model for end-stage liver disease.